1 I ntroduction of New Laboratory Diagnostics especially liquid culture, line probe assay and Xpert MTB/RIF diagnostic Test in Indonesia BY DYAH ERTI MUSTIKAWATI,

Slides:



Advertisements
Similar presentations
UNDP RBA Workshop on MDG-Based National Development Strategies Module 4: Health Strategies UN Millennium Project February 27-March 3, 2006.
Advertisements

DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.
Diagnosis of Smear negative pulmonary TB in high HIV settings: RESEARCH PRIORITIES Haileyesus Getahun, Stop TB, WHO. Expert consultation on TB/HIV research.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Agenda Background Current testings Xpert MTB/RIF product PAGE | 1.
CONFIDENTIAL AND PROPRIETARY
The Roadmap to Successful Xpert Implementation - 37 steps -
Karin Weyer WHO Stop TB Department Stop TB Partnership Global Laboratory Initiative.
MDR-TB GLOBALLY AND IN THE REGION 2013 Dr Samiha Baghdadi Medical officer – STB WHO – EMRO Cairo March 2014.
Planning in line with the Stop TB Strategy and the Global Plan to Stop TB, Dr Win Maung Programme Manager National Tuberculosis Programme Ministry.
From DOTS to the Stop TB Strategy Building on Achievements for Future Planning Stop TB Partnership Symposium at the 37 th UNION World Conference on TB.
MYCOBACTERIUM BOVIS SULTANETE OF OMAN DR.SAMAH AL-SHARIF HEAD OF VETERINARY QUARANTINE SECTION AT MUSCAT INT. AIRPORT THE REGIONAL SEMINARFOR OIE NATIONAL.
PPM-DOTS in Cambodia Working with Private Pharmacies DOTS Expansion WG Meeting Paris 15 th October 2008 Dr. Mao Tan Eang Director National Center for TB.
Improving diagnosis TB laboratory strengthening.
PPM SUBGROUP MEETING Cairo, 3-5 June 2008 Involving all health care providers in the MDR and XDR-TB response Matteo Zignol Stop TB Department World Health.
The Global Laboratory Initiative Assisting countries to implement the WHA resolution on MDR-TB Karin Weyer, WHO-STB, GLI secretariat John Ridderhof, CDC,
Country Update: Tuberculosis in Thailand
Dr R Ramachandran 5 th Joint International Monitoring Mission to Review NTP Thailand 5th JMM Thailand.
Key elements to develop a national strategic plan for TB control Malgosia Grzemska Stop TB Department WHO, Geneva, Switzerland EURO/TBTEAM Regional Workshop.
Implementation of Diagnostics in Resource-Limited Settings Amy Piatek Global Health Bureau, Office of Health, Infectious Diseases & Nutrition U.S. Agency.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Washington D.C., USA, July 2012www.aids2012.org A National Program Manager’s Perspective on HIV/TB Integration Dr Owen Mugurungi Director – AIDS.
International Standards of Tuberculosis Care Implementation by Pulmonologists in Private Practice in Jakarta E. Burhan 1, M. A. Nawas 1, D. Kusumo Sutoyo.
Accelerating PMDT scale up in Ethiopia
GUIDELINES & TOOLS for HOSPITAL DOTS LINKAGE (HDL)
Country Progress Report Philippines
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Country Progress Report VIET NAM
Early and Improved TB case detection through the use of GeneXpert technology in Nepal.
Integrating TB into PWID Services in Indonesia The Works in Progress Dr Siti Nadia, NAP Manager; Dr Dyah Erti Mustikawati, NTP Manager Melbourne AIDS Conference.
China TB Control Progress Report The ninth Technical Advisory Group and National TB Programme Managers meeting for TB control in the Western Pacific Region.
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
COMPREHENSIVE APPROACH TO TB DIAGNOSIS
Accelerating TB/HIV activities in Zambia Alwyn Mwinga 2007 HIV Implementers Meeting 20 June 2007.
Xpert in the diagnostic algorithm of pulmonary TB in adult patients who are neither high risk for HIV, nor high risk for MDR-TB Preparations for the global.
RNTCP: DOTS Expansion and plans for DOTS-Plus
Mongolia Progress Report Dr. D. Otgontsetseg, Head of recording and reporting unit, TB surveillance and research department, NCCD The ninth Technical Advisory.
Progress and Plans for PPM in the Western Pacific Region Fifth PPM DOTS Subgroup Meeting Cairo, Egypt.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Monitoring Drug Resistant Tuberculosis Treatment in Brazil through an Innovative Web-based Information System Dr. Luis Gustavo Bastos Management Sciences.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
Experience with Tb diagnostics and Scale up of services Botswana, Nigeria, and Tanzania Ernest Ekong, MD,MPH National Clinical Coordinator Harvard PEPFAR.
ISTC The Indonesian Experience Erlina Burhan Indonesian Society of Respirology ISTC Task Force Indonesian Medical Association.
Japan Dr. Ismail M. Aboshama Zidan Surveillance Coordinator of NTP-Egypt Action Plan to Strengthen Laboratory Diagnostic.
Large Hospitals DEWG – Group Work Report. Participants Indonesia Philippines South Africa Viet Nam Korea China Partners: KNCV, WHO, Gates.
Pioneering IMAI: Developing an integrated approach in Uganda Dr Elizabeth Madraa, Program Manager National STD/AIDS Control Program MOH - UGANDA 5 th Dec.
Revision of new diagnostics for TB
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.
Strengthening National Lab. Network for diagnosis of TB and HIV: Challenges and solutions. Nicholas Wambua MD; MPH; DTCE. Technical Advisor -Tuberculosis.
TB notification.
National Tuberculosis Control Program in Bangladesh : Progress Report Dr. Shamim Sultana Deputy Programme Manager, TB National TB Control Programme.
Early TB case detection in pre-trial detention centers (SIZOs) and prison colonies in Ukraine 46 th Union World Conference on Lung Health Cape Town, South.
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Control of tuberculosis in Serbia:
TB- HIV Collaborative activities in Romania- may 2006 status
Summary of changes in the RNTCP technical guidelines in
Country Progress Report Cambodia
Lessons learned from Hospital DOTS Linkage (HDL) in Yogyakarta Indonesia Jan Voskens MPH, KNCV GTI/UAB.
Key issues in DOTS implementation
Introducing new drugs and shorter regimen
Update on SBCC Activities of Challenge TB Bangladesh
Public-Public Mix for DOTS Indonesia’s Experience
Objectives of Session Provide an overview of the development of Compendium Explain the organization of the Compendium and how indicators are used Provide.
5th DEWG meeting Conclusions
South Africa: From ProTest to Nationwide Implementation
The STOP TB Strategy – 2009 VISION: A TB-free world
5th edition NTP MANUAL OF PROCEDURES Chapter 1: Introduction
Presentation transcript:

1 I ntroduction of New Laboratory Diagnostics especially liquid culture, line probe assay and Xpert MTB/RIF diagnostic Test in Indonesia BY DYAH ERTI MUSTIKAWATI, NTP Manager, MOH-Indonesia REGIONAL WORKSHOP ON TB CONTROL PLANNING, IMPLEMENTATION AND MONITORING Jakarta, Indonesia, May 2012

Background 2  Earlier and improve TB case detection to reduce the diagnostic delays are global and national priorities for TB control  Alarming increases in MDR-TB  TBMDR pilot implemetentation and KAP survey of Private Practitioners in 12 provinces  Low reported of HIV-associated TB largely goes undetected due to the limitations of current diagnostic techniques  WHO endorsed Xpert MTB/RIF in December 2010 and recommended to implement it in specific settings  Xpert MTB/RIF expect to improve TB diagnosis in HIV patient and expand capacity as proxy to diagnose MDR-TB.

6 Pilars Indonesia Public Private Mix (INA-PPM) Comprehensive Model Toward Universal Access to Qualified TB care Community System Strengthening -Function as advocator  raise fund and commitment, - Increase public awareness, function as public watch to ensure deliveries of quality services, -increasing awareness of right and responsibility of the patients (patient's charter). -Social Mobilization, suspect identification, increasing demand creation, intensifying the services of TB in slum areas and prison -Leading: NGO, FBO, CSO -TA: FHI, other partners Qualified TB Diagnostic -Approach: Strengthening lab network and Quality Assurance (public and private)  DST, Culture and Microscopic -Leading: Directorate of Medical Support - TA: KNCV and JATA Pelayanan Rumah Sakit Publik/Swasta - Approach : Hospital Accreditation, Implementation TB DOTS as Minimum Standard requirement for accreditation of Hospitals - Leading: Directorates of Referral Health Services -TA: KNCV Quality DOTS services by Private Practitioners and Specialist Quality of anti TB Drug Dispensing and rational Use of Drug - Approach: Implementation of ISTC for all TB care and treatment from all care providers, increasing professional responsibility to cure TB patients, rewarding through cumulative credits mechanism for licensing/certification -Leading: IMA -TA: ATS, -Approach: law enforcement, establishment of networking and monitoring system, WHO prequalification -Leading: Indonesian Pharmacist Association, DG of Pharmaceutical Services, Indonesian FDA -TA: USP and MSH Basic DOTS Services At Puskesmas -Approach: Surveillance System Strengthening and MIFA, Improving quality of care, increasing coverage of TBHIV, reaching un-reach pop at remote are (DTPK), increasing referral to Quality DOTS Services -Leading: NTP -TA: WHO, FHI and other partners

Current Lab Network/Services 4  Microscopic Labs  at all PHCs, Clinics and hospitals (around 10,000 centers)  National EQA System is still under construction  5 labs have reach international performance and certified for 1 st and 2 nd line DST. 1.BBLK Surabaya, East java 2.Microbiology UI, Jakarta 3.RS Persahabatan, Jakarta 4.BLK Bandung, West Java 5.NEHCRI Makassar, South Sulawesi  3 of those labs are National TB Reference Lab (NRL). 1.BBLK Surabaya (NRL for culture/DST) 2.Microbiology UI (NRL for research and biomoleculer) 3.BLK Bandung (NRL for microscopic)

Certified Culture/DST Laboratories Microbiology - UI DKI Jakarta BLK BandungPersahabatan Hosp. West Java East JavaSouth Sulawesi BBLK Surabaya NEHCRI Makassar

National TB Reference Laboratories Microbiology - UI NRL for research & Biomoleculer BLK Bandung NRL for Microscopic NRL for Culture/DST BBLK Surabaya

Microbiology - UI BBLK Surabaya NEHCRI Makassar BLK Bandung Persahabatan Hosp. Adam Malik Hosp. BBLK Palembang BLK Jayapura BLK Banjarmasin UGM-DIY BLK Semarang Sanglah Hosp BLK-Lampung Rotinsulu Hosp. BLK Samarinda BBKPM Solo BBLK Makassar Note : Certified : 5 labs Renovated: BSL 2 plus: 5 labs Next expansion of C/DST labs: 7 labs Expansion Plan of Culture/DST Lab until 2014

Key areas of progress since 2009 No Key Areas National TB Lab action Plan-Available 2National TB Reference Lab-3 labs 3Certified FL DST Lab3 labs5 labs 4Certified SL DST Lab-5 labs 5Improve Biosafety (Renovation of Culture/DST Lab to meet BSL 2 plus standard) -4 labs completed 2 labs in progress 6Implementation of LPA-3 labs 7Implementation of GeneXpert-5 labs (up to March)

National TB Lab Action Plan,

Cost Sharing in Establishing BSL 2 plus Lab for Culture/DST 10 Lab/ Institution DesignRenovationEquipmentsTrainingTechnical Assistance Microbiology UGM TBCAP TBCARE I BLK SemarangTBCAPAPBD, TBCAP APBN, TBCAP, GF-ATM TBCAPTBCAP TBCARE I BLK JayapuraTBCAP APBN, TBCAP, GF-ATM TBCAP, GF-ATM TBCAP TBCARE I Adam Malik Hospital TBCAPGF-ATM TBCAP, GF-ATM TBCAP TBCARE I BLK Banjarmasin GF-ATM APBN GF-ATM TBCAP, GF-ATM TBCAP TBCARE I

Renovation of TB Culture/DST Lab: Microbiology UGM 11

12 Renovation of TB Culture/DST Lab: BLK Jayapura, Papua

13 Renovation of TB Culture/DST Lab: BLK Semarang, Central Java

Introduction of liquid culture and LPA and roll out of Xpert MTB/RIF - current status  2 out of 5 certified DST lab applying liquid culture (MGIT 960 and manual MGIT) Microbiology UI, Jakarta (MGIT 960) and NEHCRI Makassar (Manual MGIT)  Expand TB plan: will support MGIT 960 and HAIN for 2 labs BBLK Surabaya (NRL for culture/DST) and Persahabatan Hospital (MDR TB Treatment Centre)  3 Labs already implemented LPA (Hain test) Microbiology UI, Jakarta; NEHCRI Makassar; Soetomo Hospital, Surabaya  GeneXpert: 17 unit GeneXpert machines and 1700 cartidges have been procured. Implementation of GeneXpert will be done in step wise manner. 5 iniatial sites are operating on March 2012.

Introduction of LPA: Study of GenoType®MTBDR (FL & SL) from HAIN Life Science  The studies are performed in Microbiology, Medical Faculty, University of Indonesia (NRL for TB research and molecular)  GenoType®MTBDRplus evaluation for rapid detection of MDR-TB in TB isolates (phase I)  GenoType®MTBDRplus Evaluation for rapid detection of MDR-TB in patients with sputum smear positive pulmonary TB (phase II)  Performance of Genotype ® MTBDR sl assay for ethambutol, ofloxacin, amikacin and kanamycin resistance testing in MDR and rifampicin resistant M. tuberculosis strains (in progress)

Result of GenotypeMTBDRplus study for rapid detection of MDR-TB in TB isolates (phase I)* Rif resistanceINH resistanceMDR TB Sensitivity90.63%69.49%67.02 % Specificity95.31%92.86%95.45 % PPV96.67%96.47%95.45 % NPV87.14%52.00%67.02 % Notes: Isolates/Strains come from several provinces in Indonesia

On going research of Genotype® MTBDRplus (Phase II) Setting:  300 samples sputum from MDR-TB suspect  Term: Februari 2011-end of March 2012  Compare GenotypeMTBDRplus result with liquid culture (MGIT960)  Observe: Sensitivity, specificity, positive predictive value, and negative predictive value  Data analysis: in progress

On going research of Genotype® MTBDRsl Setting:  235 MDR-TB isolates sample from confirmed MDR-TB patients  Term: August 2011-end of March 2012  Compare GenotypeMTBDRsl with liquid culture (MGIT960).  Observe: sensitivity, specificity, positive predictive value, and negative predictive value  Data: in progress

Introduction of Xpert MTB/Rif (GeneXpert) GeneXpert Implementation Steps Step1: workshop Step 2: select the team Xpert focal person Country GeneXpert Advisory team (C-GAT) Research institutes for OR Step 3: Selection of sites Step 4: developing country specific implementation action plan and agree roles Step 5: develop OR plan and agree on roles Step 6: ToT and training Step 7: implementation

Placement plan of 17 GeneXpert machines 1.Microbiology – UI 2.Persahabatan Hosp 3.Pengoyoman Hosp. (Prison) 1.Soetomo Hosp. 2.BBLK Surabaya 3.Saiful Anwar Hosp. 1.Labuang Baji Hosp. 2.NEHCRI Makassar 1.BLK Papua 1.Adam Malik Hosp 1.Hasan sadikin Hosp. 2.BLK Bandung c 1.Microbiology UGM 1.Moewardi Hosp. 2.Kariadi Hosp. 3.Cilacap Hosp. (Prison) 1.Sanglah Hosp.

Certified DST Lab. for confirmation of Xpert result Adam Malik Hosp. BLK Papua BBLK Palembang BLK SemarangUGM Lab Certified lab Under capacity building process towards certified lab BLK Banjarmasin

GeneXpert Workshop TOT 22

MoU Signing between MoH and GeneXpert Sites 23

GeneXpert On site training 24 Soetomo Hospital Moewardi HospitalPersahabatan Hospital

The Data of Genexpert Examination up to 31 Mar NoSites Date start implementation Number of Suspects MTB positive/ Rif resistant Patient put on treatm ent Remark MDR TB TB HIVTotal 1 Persahabatan Hosp.05 March patient are under evaluation from the clinicians expert team 2Moewardi Hosp.08 March Microbiology UI12 March patient reffer to RS Persahabatan 4Soetomo Hosp.20 March Total

26 The Data of Genexpert Examination up to 30 April 2012 NoSites Date start implementation Number of Suspects MTB positive/Rif resistant Patient put on treatment Remark MDR TB TB HIV MDR TB-HIV Total 1 Persahabatan Hosp.05 March Patient are under evaluation from the clinician expert team 2Moewardi Hosp.08 March Microbiology UI12 March Soetomo Hosp.20 March Patient are under evaluation from the clinician expert team 5 Hasan Sadikin Hosp.03 April Total 20342

The logistic of cartridge 27 Totally number cartridge in wire house (PT Fajar Mas Murni) = 420 The total number of cartridge received for each sites (for examination and Keeping in sites wire house)

Challenges in introduction and roll out of newer diagnostics (LPA &Xpert MTB/RIF)  Expensive machines and consumables.  Quality assurance, maintenance and calibration.  Capacity to treat more MDR TB patients (Human Resources, infrastructure, funding etc)  Availability of SL Drugs, not only in country level but also globally  Limited Quality assured Culture/DST lab to support confirmation of LPA and Xpert TB/Rif result.  Limited MDR TB treatment centre.

Conclusion  TB Laboratory plays main role in MDR TB diagnosis to support PMDT program.  Expansion of quality assured culture/DST lab and MDR TB treatment centre are crucial to achieve national target.  Utilizing new TB diagnostic tools as a breakthrough to avoid delays in treatment.  Increasing in diagnosis capacity must be followed by increasing of treatment capacity as well.

30 Thank You